Aging affects high-density lipoprotein composition and function

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 9, 2013, Pages 1442-1448

  Holzer, Michael ^a   Trieb, Markus ^a   Konya, Viktoria ^a   Wadsack, Christian ^a   Heinemann, Akos ^a   Marsche, Gunther ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Anti oxidative activity; Cardiovascular disease; Paraoxonase; Proteome

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER; CLUSTERIN; COMPLEMENT COMPONENT C3; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID; PROTEINASE; SPHINGOMYELIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; LIPID COMPOSITION; MACROPHAGE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN ISOLATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84879811932     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2013.06.004     Document Type: Article

References (51)

1. W.P. Castelli, R.J. Garrison, P.F. Wilson, R.D. Abbott, S. Kalousdian, W.B. Kannel, Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study, JAMA 256 (1986) 2835-2838. (Pubitemid 17178361)
2. G.H. Rothblat, M.C. Phillips, High-density lipoprotein heterogeneity and function in reverse cholesterol transport, Curr. Opin. Lipidol. 21 (2010) 229-238.
3. A.V. Khera, M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M.F. Burke, K. Jafri, B.C. French, J.A. Phillips, M.L. Mucksavage, R.L. Wilensky, E.R. Mohler, G.H. Rothblat, D.J. Rader, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N. Engl. J. Med. 364 (2011) 127-135.
4. C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D.M. Shih, A. Chroni, K. Yonekawa, S. Stein, N. Schaefer, M. Mueller, A. Akhmedov, G. Daniil, C. Manes, C. Templin, C. Wyss, W. Maier, F.C. Tanner, C.M. Matter, R. Corti, C. Furlong, A.J. Lusis, A. von Eckardstein, A.M. Fogelman, T.F. Luscher, U. Landmesser, Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease, J. Clin. Invest. 121 (2011) 2693-2708.
5. G.W. Cockerill, K.A. Rye, J.R. Gamble, M.A. Vadas, P.J. Barter, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1987-1994.
6. S. Parthasarathy, J. Barnett, L.G. Fong, High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein, Biochim. Biophys. Acta 1044 (1990) 275-283. (Pubitemid 20151285)
7. I.S. Yuhanna, Y. Zhu, B.E. Cox, L.D. Hahner, S. Osborne-Lawrence, P. Lu, Y.L. Marcel, R.G. Anderson, M.E. Mendelsohn, H.H. Hobbs, P.W. Shaul, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat. Med. 7 (2001) 853-857. (Pubitemid 32691642)
8. C.A. Bursill, M.L. Castro, D.T. Beattie, S. Nakhla, E. van der Vorst, A.K. Heather, P.J. Barter, K.A. Rye, High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 1773-1778.
9. B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen, G. Hindy, H. Holm, E.L. Ding, T. Johnson, H. Schunkert, N.J. Samani, R. Clarke, J.C. Hopewell, J.F. Thompson, M. Li, G. Thorleifsson, C. Newton-Cheh, K. Musunuru, J.P. Pirruccello, D. Saleheen, L. Chen, A. Stewart, A. Schillert, U. Thorsteinsdottir, G. Thorgeirsson, S. Anand, J.C. Engert, T. Morgan, J. Spertus, M. Stoll, K. Berger, N. Martinelli, D. Girelli, P.P. McKeown, C.C. Patterson, S.E. Epstein, J. Devaney, M.S. Burnett, V. Mooser, S. Ripatti, I. Surakka, M.S. Nieminen, J. Sinisalo, M.L. Lokki, M. Perola, A. Havulinna, U. de Faire, B. Gigante, E. Ingelsson, T. Zeller, P. Wild, P.I. de Bakker, O.H. Klungel, A.H. Maitland-van der Zee, B.J. Peters, A. de Boer, D.E. Grobbee, P.W. Kamphuisen, V.H. Deneer, C.C. Elbers, N.C. Onland-Moret, M.H. Hofker, C. Wijmenga, W.M. Verschuren, J.M. Boer, Y.T. van der Schouw, A. Rasheed, P. Frossard, S. Demissie, C. Willer, R. Do, J.M. Ordovas, G.R. Abecasis, M. Boehnke, K.L. Mohlke, M.J. Daly, C. Guiducci, N.P. Burtt, A. Surti, E. Gonzalez, S. Purcell, S. Gabriel, J. Marrugat, J. Peden, J. Erdmann, P. Diemert, C. Willenborg, I.R. Konig, M. Fischer, C. Hengstenberg, A. Ziegler, I. Buysschaert, D. Lambrechts, F. Van de Werf, K.A. Fox, N.E. El Mokhtari, D. Rubin, J. Schrezenmeir, S. Schreiber, A. Schafer, J. Danesh, S. Blankenberg, R. Roberts, R. McPherson, H. Watkins, A.S. Hall, K. Overvad, E. Rimm, E. Boerwinkle, A. Tybjaerg-Hansen, L.A. Cupples, M.P. Reilly, O. Melander, P.M. Mannucci, D. Ardissino, D. Siscovick, R. Elosua, K. Stefansson, C.J. O'Donnell, V. Salomaa, D.J. Rader, L. Peltonen, S.M. Schwartz, D. Altshuler, S. Kathiresan, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study, Lancet 380 (2012) 572-580.
10. U. Landmesser, A. von Eckardstein, J. Kastelein, J. Deanfield, T.F. Luscher, Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme, Eur. Heart J. 33 (2012) 1712-1715.
11. G. Marsche, M.D. Saemann, A. Heinemann, M. Holzer, Inflammation alters HDL composition and function: Implications for HDL-raising therapies, Pharmacol. Ther. 137 (2013) 341-351.
12. M. Holzer, P. Wolf, S. Curcic, R. Birner-Gruenberger, W. Weger, M. Inzinger, D. El-Gamal, C. Wadsack, A. Heinemann, G. Marsche, Psoriasis alters HDL composition and cholesterol efflux capacity, J. Lipid Res. 53 (2012) 1618-1624.
13. M. Holzer, R. Birner-Gruenberger, T. Stojakovic, D. El-Gamal, V. Binder, C. Wadsack, A. Heinemann, G. Marsche, Uremia alters HDL composition and function, J. Am. Soc. Nephrol. 22 (2011) 1631-1641.
14. T. Weichhart, C. Kopecky, M. Kubicek, M. Haidinger, D. Doller, K. Katholnig, C. Suarna, P. Eller, M. Tolle, C. Gerner, G.J. Zlabinger, M. van der Giet, W.H. Horl, R. Stocker, M.D. Saemann, Serum amyloid A in uremic HDL promotes inflammation, J. Am. Soc. Nephrol. 23 (2012) 934-947.
15. M. Tolle, T. Huang, M. Schuchardt, V. Jankowski, N. Prufer, J. Jankowski, U.J. Tietge, W. Zidek, M. van der Giet, High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A, Cardiovasc. Res. 94 (2012) 154-162.
16. J. Watanabe, C. Charles-Schoeman, Y. Miao, D. Elashoff, Y.Y. Lee, G. Katselis, T.D. Lee, S.T. Reddy, Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis, Arthritis Rheum. 64 (2012) 1828-1837.
17. N.N. Mehta, R. Li, P. Krishnamoorthy, Y. Yu, W. Farver, A. Rodrigues, A. Raper, M. Wilcox, A. Baer, S. Der Ohannesian, M. Wolfe, M.P. Reilly, D.J. Rader, A. Van Voorhees, J.M. Gelfand, Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis, Atherosclerosis 224 (2012) 218-221.
18. K. Alwaili, D. Bailey, Z. Awan, S.D. Bailey, I. Ruel, A. Hafiane, L. Krimbou, S. Laboissiere, J. Genest, The HDL proteome in acute coronary syndromes shifts to an inflammatory profile, Biochim. Biophys. Acta 1821 (2012) 405-415.
19. K.C. Vickers, A.T. Remaley, Functional diversity of HDL cargo, J. Lipid Res. (2013), http://dx.doi.org/10.1194/jlr.R035964.
20. A.S. Shah, L. Tan, J. Lu Long, W.S. Davidson, The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond, J. Lipid Res. (2013), http://dx.doi.org/10.1194/jlr. R035725.
21. C. Charles-Schoeman, Y.Y. Lee, V. Grijalva, S. Amjadi, J. Fitz Gerald, V.K. Ranganath, M. Taylor, M. McMahon, H.E. Paulus, S.T. Reddy, Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis, Ann. Rheum. Dis. 71 (2012) 1157-1162.
22. B.J. Van Lenten, S.Y. Hama, F.C. de Beer, D.M. Stafforini, T.M. McIntyre, S.M. Prescott, B.N. La Du, A.M. Fogelman, M. Navab, Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures, J. Clin. Invest. 96 (1995) 2758-2767.
23. A. Kontush, M. Lhomme, M.J. Chapman, Unravelling the complexities of the HDL lipidome, J. Lipid Res. (2013), http://dx.doi.org/10.1194/jlr.R036095.
24. H. Berrougui, M. Isabelle, M. Cloutier, G. Grenier, A. Khalil, Age-related impairment of HDL-mediated cholesterol efflux, J. Lipid Res. 48 (2007) 328-336. (Pubitemid 46220599)
25. L. Jaouad, C. de Guise, H. Berrougui, M. Cloutier, M. Isabelle, T. Fulop, H. Payette, A. Khalil, Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups, Atherosclerosis 185 (2006) 191-200. (Pubitemid 43117568)
26. M. Holzer, M. Gauster, T. Pfeifer, C. Wadsack, G. Fauler, P. Stiegler, H. Koefeler, E. Beubler, R. Schuligoi, A. Heinemann, G. Marsche, Protein carbamylation renders high-density lipoprotein dysfunctional, Antioxid. Redox Signal. 14 (2011) 2337-2346.
27. W. Sattler, D. Mohr, R. Stocker, Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence, Methods Enzymol. 233 (1994) 469-489.
28. Y. Zhao, Y.L. Marcel, Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins, Biochemistry 35 (1996) 7174-7180. (Pubitemid 26182109)
29. V. Binder, S. Ljubojevic, J. Haybaeck, M. Holzer, D. El-Gamal, R. Schicho, B. Pieske, A. Heinemann, G. Marsche, The myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitors, Arterioscler. Thromb. Vasc. Biol. 33 (2013) 1020-1027.
30. G. Marsche, S. Frank, A. Hrzenjak, M. Holzer, S. Dirnberger, C. Wadsack, H. Scharnagl, T. Stojakovic, A. Heinemann, K. Oettl, Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo, Circ. Res. 104 (2009) 750-757.
31. T. Kelesidis, J.S. Currier, D. Huynh, D. Meriwether, C. Charles-Schoeman, S.T. Reddy, A.M. Fogelman, M. Navab, O.O. Yang, A biochemical fluorometric method for assessing the oxidative properties of HDL, J. Lipid Res. 52 (2011) 2341-2351.
32. Z.F. Stephan, E.C. Yurachek, Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL, J. Lipid Res. 34 (1993) 325-330. (Pubitemid 23067537)
33. A. Kontush, M.J. Chapman, Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities, Curr. Opin. Lipidol. 21 (2010) 312-318.
34. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, B.N. La Du, Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase, J. Clin. Invest. 101 (1998) 1581-1590. (Pubitemid 28198486)
35. G.K. Marathe, G.A. Zimmerman, T.M. McIntyre, Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles, J. Biol. Chem. 278 (2003) 3937-3947. (Pubitemid 36801125)
36. B. Mackness, M. Mackness, Anti-inflammatory properties of paraoxonase-1 in atherosclerosis, Adv. Exp. Med. Biol. 660 (2010) 143-151.
37. D. Hine, B. Mackness, M. Mackness, Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation, IUBMB Life 64 (2012) 157-161.
38. L. Gaidukov, A.R. Nager, S. Xu, M. Penman, M. Krieger, Glycine dimerization motif in the N-terminal transmembrane domain of the high density lipoprotein receptor SR-BI required for normal receptor oligomerization and lipid transport, J. Biol. Chem. 286 (2011) 18452-18464.
39. P.A. Mak, H.R. Kast-Woelbern, A.M. Anisfeld, P.A. Edwards, Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors, J. Lipid Res. 43 (2002) 2037-2041. (Pubitemid 35471069)
40. T. Vaisar, S. Pennathur, P.S. Green, S.A. Gharib, A.N. Hoofnagle, M.C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, H. Chea, R.H. Knopp, J. Brunzell, R. Geary, A. Chait, X.Q. Zhao, K. Elkon, S. Marcovina, P. Ridker, J.F. Oram, J.W. Heinecke, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL, J. Clin. Invest. 117 (2007) 746-756. (Pubitemid 46348533)
41. R.C. Strunk, K.S. Kunke, P.C. Giclas, Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro, Immunology 49 (1983) 169-174. (Pubitemid 13120377)
42. R. Oksjoki, P.T. Kovanen, M.O. Pentikainen, Role of complement activation in atherosclerosis, Curr. Opin. Lipidol. 14 (2003) 477-482. (Pubitemid 37297302)
43. K. Niemi, L. Teirila, J. Lappalainen, K. Rajamaki, M.H. Baumann, K. Oorni, H. Wolff, P.T. Kovanen, S. Matikainen, K.K. Eklund, Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway, J. Immunol. 186 (2011) 6119-6128.
44. I. Seres, G. Paragh, E. Deschene, T. Fulop Jr., A. Khalil, Study of factors influencing the decreased HDL associated PON1 activity with aging, Exp. Gerontol. 39 (2004) 59-66. (Pubitemid 38068260)
45. T. Bhattacharyya, S.J. Nicholls, E.J. Topol, R. Zhang, X. Yang, D. Schmitt, X. Fu, M. Shao, D.M. Brennan, S.G. Ellis, M.L. Brennan, H. Allayee, A.J. Lusis, S.L. Hazen, Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk, JAMA 299 (2008) 1265-1276. (Pubitemid 351439073)
46. B. Mackness, W. Turkie, M. Mackness, Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease, Arch. Med. Sci. 9 (2013) 8-13.
47. P.J. Patel, A.V. Khera, K. Jafri, R.L. Wilensky, D.J. Rader, The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease, J. Am. Coll. Cardiol. 58 (2011) 2068-2075.
48. B. Foger, S. Santamarina-Fojo, R.D. Shamburek, C.L. Parrot, G.D. Talley, H.B. Brewer Jr., Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL, J. Biol. Chem. 272 (1997) 27393-27400. (Pubitemid 27452707)
49. R. van Haperen, H. Samyn, T. van Gent, A.J. Zonneveld, M. Moerland, F. Grosveld, H. Jansen, G.M. Dallinga-Thie, A. van Tol, R. de Crom, Novel roles of hepatic lipase and phospholipid transfer protein in VLDL as well as HDL metabolism, Biochim. Biophys. Acta 1791 (2009) 1031-1036.
50. A. van Tol, Phospholipid transfer protein, Curr. Opin. Lipidol. 13 (2002) 135-139. (Pubitemid 34280764)
51. S. Sankaranarayanan, J.F. Oram, B.F. Asztalos, A.M. Vaughan, S. Lund-Katz, M.P. Adorni, M.C. Phillips, G.H. Rothblat, Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux, J. Lipid Res. 50 (2009) 275-284.